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Abstract 
Objective- The mechanisms underlying accelerated atherosclerosis in metabolic 
syndrome (MetS) patients remain poorly defined. In the mouse, complete disruption of 
insulin receptor substrate-2 (Irs2) causes insulin resistance, MetS-like manifestations, and 
accelerates atherosclerosis. Here, we performed human, mouse and cell culture studies 
to gain insight into the contribution of defective Irs2 signaling to MetS-associated 
alterations. 
 
Methods and Results- In circulating leukocytes from insulin-resistant MetS patients, Irs2 
and Akt2 mRNA levels inversely correlate with plasma insulin levels and HOMA index and 
are reduced compared to insulin-sensitive MetS patients. Notably, a moderate reduction 
in Irs2 expression in fat-fed apolipoprotein E-null mice lacking one allele of Irs2 (apoE-/-
Irs2+/-) accelerates atherosclerosis compared to apoE-null controls, without affecting 
plaque composition. Partial Irs2 inactivation also increases CD36 and SRA scavenger 
receptor expression and modified LDL uptake in macrophages, diminishes Akt2 and Ras 
expression in aorta, and enhances expression of the pro-atherogenic cytokine MCP1 in 
aorta and primary vascular smooth muscle cells (VSMCs) and macrophages. Inhibition of 
AKT or ERK1/2, a downstream target of RAS, upregulates Mcp1 in VSMCs. 
 
Conclusions- Enhanced levels of MCP1 resulting from reduced IRS2 expression and 
accompanying defects in AKT2 and Ras/ERK1/2 signaling pathways may contribute to 
accelerated atherosclerosis in MetS states.  
 
KEY WORDS: Insulin resistance/metabolic syndrome, atherosclerosis, IRS2, AKT, ERK. 
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Condensed Abstract 
 
Here we investigated the role of IRS2-dependent signaling in MetS states by analyzing 
leukocytes from MetS patients, apoE-null mice with partial inactivation of Irs2 and cultured 
cells. Our results suggest that MCP1 upregulation resulting from reduced IRS2 
expression and accompanying defects in AKT2 and Ras/ERK1/2 signaling may contribute 
to MetS-induced atherosclerosis. 
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The metabolic syndrome (MetS) is defined by the presence of at least 3 of the following 
abnormalities: abdominal obesity, glucose intolerance, hypertension, low HDL-cholesterol 
levels and/or hypertriglyceridemia.1, 2 Patients with MetS and type-2 diabetes mellitus 
(T2DM) have 2-5 times higher risk of atherosclerosis, a chronic inflammatory disease that 
results from interactions between modified lipoproteins and cells of the arterial wall, 
including endothelial, immune, and vascular smooth muscle cells (VSMCs).3-5 Among the 
different cardiovascular risk factors that precipitate atherosclerosis and associated 
cardiovascular disease (CVD), T2DM and MetS are becoming the most relevant given 
that the prevalence of these metabolic diseases is expected to increase by 165% in the 
next 40 years, representing the health plague of the 21st century.2 Importantly, the 
incidence of CVD increases when T2DM and the MetS co-exist.1, 2 Population aging and 
acquisition of sedentary lifestyle patterns (e.g. obesity and physical inactivity) are major 
driving forces behind these metabolic diseases. A number of alterations in endothelial 
cells, VSMCs and platelets have been identified which may accelerate atherosclerosis, 
plaque instability and thrombus formation in T2DM/MetS patients, however the underlying 
mechanisms remain ill defined.2, 6, 7 Many MetS patients display insulin resistance (IR), 
which seems to play a pivotal role in the development of both atherogenic dyslipidemia 
and T2DM.1 Therefore, IR is an attractive target for prevention of CVD. However, whether 
IR management per se might reduce CVD risk remains unknown.  
Upon binding to the insulin receptor (INS-R), insulin exerts its action through insulin-
receptor substrate proteins (IRS1-4).8 Studies in genetically-modified mice have 
highlighted a major role of IRS2 in β-cell function, glucose and insulin homeostasis, and 
atherosclerosis development. First, Irs2-null mice (Irs2-/-) display a T2DM/MetS-like 
phenotype, including hyperglucemia, hyperinsulinemia, IR and hypertension.9-11 Second, 
global Irs2-deficiency in apoE-null mice (apoE-/-Irs2-/-) aggravates atherosclerosis 
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compared to apoE-/- counterparts with intact Irs2.12, 13 Doubly deficient apoE-/-Irs2-/- mice 
exhibit hyperinsulinemia, IR and increased glucose intolerance and a positive correlation 
between circulating insulin levels and atherosclerotic burden,12 consistent with findings in 
Lepob/ob:LDLr-/- and Lepob/ob:apoE-/- mice, two additional models of IR-dependent 
accelerated atherosclerosis.14 It is noteworthy that while whole body Irs2 ablation 
aggravated atherosclerosis,12, 13 the effects of macrophage-specific defective insulin 
signaling are controversial. Indeed, Ins-r-deficient bone-marrow transplant enhanced 
atherosclerosis in LDLr-/- mice,15 however macrophage-specific inactivation of Ins-r or Irs2 
decreased atherosclerosis in apoE-/- mice.13 The reasons for these controversial findings 
remain to be established.  
The two main downstream effectors of IRS proteins are the phosphatidylinositol-3 
kinase (PI-3K)/V-akt murine thymoma viral oncogene homolog kinase (AKT) and the 
Ras/Raf/extracellular signal-regulated kinase (ERK) pathways.8 Marked reductions in Ins-
r, Irs2 and Akt2 gene expression have been reported in pancreatic islets from T2DM 
patients.16 Here we have tested the hypothesis that impaired IRS2 signaling is a 
mechanism contributing to accelerated atherosclerosis in MetS states. To this end, we 
have analyzed IRS2 signaling in white mononuclear blood cells (WMBCs) from MetS 
patients with and without IR. Additionally, we have studied apoE-null mice with an intact 
Irs2 gene (apoE-/-) or lacking one allele of Irs2 (apoE-/-Irs2+/- mice), and primary VSMCs 
and macrophages derived from these animals.  
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Materials and Methods 
Expanded Materials and Methods can be found in Supplementary Material. 
Human subjects 
In compliance with institutional guidelines, subjects were informed of the present study 
and all agreed to participate. The study was carried out in accordance with the Helsinki 
Declaration, and the Ethical Committee of the University Clinic of Navarra approved the 
protocol. The study was performed with samples from 55 unrelated individuals referred to 
our institution for routine medical work-up after 12 hours of overnight fasting. Clinical 
screenings were based on medical history, physical examination and routine analytical 
tests. Subjects were diagnosed with MetS when 3 or more of the AHA/NHLBI criteria for 
defining this condition1 were present. The following criteria were adopted: 
Central obesity: waist circumference ≥102 cm in men and ≥88 cm in women; 
hypertriglyceridemia: triglycerides ≥1.7 mmol/L or use of medication to reduce 
triglycerides; low HDL cholesterol: HDL cholesterol <1.03 mmol/L in men and <1.3 
mmol/L in women or use of medication to increase HDL cholesterol; high blood 
pressure: systolic blood pressure (SBP) ≥130 mm Hg, diastolic blood pressure (DBP) 
≥85 mm Hg, or use of antihypertensive medication; high fasting glucose: glucose ≥5.55 
mmol/L or use of medication to reduce glucose. 
 
IR was diagnosed when the homeostasis model assessment (HOMA) index (fasting 
glucose [mmol/L]×fasting insulin [µU/mL]/22.5) was equal or bigger than the median in 
normal-weight subjects plus 2.5 standard deviations (HOMA≥3.3). Using this criterium, we 
identified 30 patients with IR within the studied population.  
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Mice and diets 
Care of animals was in accordance with institutional guidelines. Irs2-/- (C57BL/6J)10 and 
apoE-/- (C57BL/6J, Charles River) mice were crossbred to generate apoE-/-Irs2+/- mice. 
Genotyping was done by PCR as described.10, 12 After weaning, male mice were 
maintained on a low-fat (control) standard diet (2.8% fat; Panlab, Barcelona, Spain) or 
placed on an atherogenic diet (10.8% total fat, 0.75% cholesterol, S4892-E010, Ssniff, 
Germany) for the indicated periods of time.  
 
 
 
 
Results 
 
Irs2 and Akt2 expression is decreased in WMBCs and inversely correlates with 
insulin levels and HOMA index in insulin-resistant MetS patients 
The demographic and clinical characteristics of the MetS patients included in our studies 
are summarized in Table 1. Patients were classified as insulin-sensitive or insulin-
resistant based on the HOMA index (see methods). No significant differences in gender 
distribution, age and frequency of cardiovascular medications were observed between 
both groups. However, insulin-resistant patients presented higher body mass index (BMI), 
waist circumference, DBP, HOMA index, and plasma levels of insulin, oxidized LDL 
(oxLDL) and metalloproteinase-9 (MMP-9), and lower plasma HDL-cholesterol levels as 
compared with insulin-sensitive patients. No significant differences in the remaining 
parameters were noted between the two groups of patients. Thus, IR is associated with 
higher risk of CVD in our cohort of MetS patients. 
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Given that total genetic ablation of Irs2 in fat-fed apoE-/- mice produces IR and 
accelerates atherosclerosis12, 13 and that IRS proteins signal in part through the PI3K/AKT 
pathway,8 we examined Irs2 and Akt expression in WMBCs from both groups of patients. 
Quantitative real-time PCR (qPCR) analysis revealed reduced Irs2 and Akt2 mRNA levels 
in insulin-resistant versus insulin-sensitive subjects, although only differences in Akt2 
reached statistical significance (Fig.1A). We also found increased expression of Irs1 in 
insulin-resistant versus insulin-sensitive individuals (p=0.029), while Akt1 and Akt3 were 
expressed at similar level in both groups of patients (Fig.1A). Correlation studies 
demonstrated a significant and positive bivariate correlation between Irs2 and Akt2 
expression in all the MetS patients (r2=0.66, p<0.001, Fig.1B), which remained highly 
significant after controlling for age and sex (r2=0.63, p<0.001), and when analyzing 
separately insulin-sensitive (r2=0.69, p<0.001) and insulin-resistant (r2=0.46, p<0.001) 
patients.  
In insulin-resistant patients, mRNA expression levels of Irs2 and Akt2 in WMBCs 
exhibited a statistically significant inverse correlation with plasma insulin levels (Fig.1C,E) 
and the HOMA index (Fig.1D,F). These associations were not observed in insulin-
sensitive patients (Irs2 vs. insulin: r2=0.039, p=0.342; Irs2 vs. HOMA: r2=0.051, p=0.278; 
Akt2 vs. insulin: r2=0.02, p=0.500; Akt2 vs. HOMA: r2=0.022, p=0.484). Additional 
association studies are presented in Supplementary Material (Tables I-IV, please see 
www.ahajournals.org). These results indicate that hyperinsulinemia and IR in MetS 
patients are associated with downregulation of Irs2 and its downstream effector Akt2 in 
WMBCs.  
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Partial inactivation of Irs2 in apoE-/- mice combined with severe 
hypercholesterolemia produces increased glucose intolerance and mild 
hyperinsulinemia and accelerates atherosclerosis 
We next sought to generate an animal model with moderate reductions in Irs2 expression 
in order to determine whether this alteration observed in insulin-resistant MetS patients 
accelerates atherosclerosis. To this end, we partially inactivated the Irs2 gene in apoE-/- 
mice, which spontaneously develop hypercholesterolemia and complex atherosclerotic 
lesions resembling those observed in humans, which can be accelerated by a high-fat 
cholesterol-rich diet.17 Mice received either standard chow or were challenged for 3 
months with a high-fat cholesterol-rich atherogenic-diet. Under either dietary regimen, 
partial disruption of Irs2 did not influence circulating glucose levels (Fig.2A,B). Similarly, 
fasting plasma insulin levels did not differ between apoE-/- and apoE-/-Irs2+/- mice fed 
control diet (Fig.2A). However, on a high-fat diet, a trend towards increased fasting 
plasma insulin was observed in apoE-/-Irs2+/- mice (1.00 ± 0.17 vs. 0.65 ± 0.14 μg/dL, 
respectively, p=0.074) (Fig.2B). Glucose tolerance measured by the area under the curve 
(AUC) was similar in apoE-/-Irs2+/- and apoE-/- mice fed control diet (Fig.2C), whereas, fat-
fed apoE-/-Irs2+/- mice were more glucose intolerant than apoE-/- counterparts on a high-fat 
diet (p<0.05, Fig.2D). Under both dietary regimens, glucose-stimulated insulin secretion 
was similar in both groups of mice, as revealed by the AUC (Fig.2C,D). Likewise, body 
weight did not differ statistically between control and fat-fed apoE-/-Irs2+/- and apoE-/- mice 
(data not shown), thus excluding obesity as a principal factor in the aforementioned 
metabolic differences developed by apoE-/-Irs2+/- mice.  
Circulating levels of total cholesterol (Total-C), HDL-C and triacylglycerides (TAG) 
were indistinguishable between apoE-/- and apoE-/-Irs2+/- mice fed either control (Fig.2E) 
or atherogenic (Fig.2F) diet. As expected, levels of plasma Total-C and TAG in fat-fed 
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mice were increased in comparison to pre-diet values. These findings suggest that lipid 
metabolism in apoE-/- mice is unaffected by deletion of one allele of Irs2.  
As shown in Fig.3A, Oil RedO staining revealed similar extent of atherosclerosis in 
the aortic arch of apoE-/- and apoE-/-Irs2+/- mice fed control diet (Total-C ∼300 mg/dL, cf. 
Fig.2E). In contrast, atherosclerosis burden was significantly increased in fat-fed apoE-/-
Irs2+/- mice (Total-C>550 mg/dL, cf. Fig.2F, post-diet values) receiving the atherogenic 
diet for 2 months (aortic root, Figure IA, please see www.ahajournals.org) and 3 months 
(aortic arch, Fig.3A). We also found that neointimal accumulation of Mac3-
immunoreactive macrophages, SMα-actin-immunoreactive VSMCs, and collagen was 
undistinguishable when comparing apoE-/- and apoE-/-Irs2+/- mice fed either standard 
chow or atherogenic diet (Fig.3B, and Fig.IB in www.ahajournals.org).  
We next investigated the consequences of reduced Irs2 expression on the uptake of 
modified LDL by macrophages, a key event in atherosclerosis.18 Macrophages from 
apoE-/-Irs2+/- mice exhibited a 30% increase in AlexaFluor488-acLDL uptake compared to 
apoE-/- controls (Fig.3C), coinciding with higher mRNA levels of CD36 and SRA (Fig.3D), 
the two main scavenger receptors involved in the uptake of modified LDLs by neointimal 
macrophages. 
 
Effect of partial Irs2 inactivation on aortic expression of genes related to insulin 
signaling 
To further investigate the underlying mechanisms by which partial inactivation of Irs2 in 
apoE-/- mice aggravates diet-induced atherosclerosis, we used a pathway-focused RT-
PCR array which profiles the expression of 84 genes related to insulin action (Table V 
and Methods in online Supplement, please see www.ahajournals.org). We analyzed 
atheroma-rich aortic tissue obtained from mice maintained for 2 months on a high-fat diet. 
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The array analysis revealed changes in the expression of 14 genes in aorta of apoE-/-
Irs2+/- vs. apoE-/- mice (3 with p=0.06 and 11 with at least p<0.05) (Fig.4). As expected, 
Irs2 mRNA expression was significantly reduced in apoE-/-Irs2+/- aorta. Among the altered 
genes, several are related with glucose and lipid metabolism (G6pc, G6pc2, LDLr) 
whereas others encode kinases and phosphatases (Dusp14, Nck1, Prkc), transcription 
factors (Cebpa, Klf10) and scaffold protein genes (Shc1). Interestingly, apoE-/-Irs2+/- aorta 
exhibited reduced Akt2, Rras and Hras1 mRNA levels. These results clearly demonstrate 
that the Irs2/Akt2/Ras insulin-signaling effector pathway is downregulated in aortic tissue 
of fat-fed apoE-/-Irs2+/- mice. 
 
Both partial Irs2 genetic inactivation and pharmacological inhibition of AKT or 
ERK1/2 enhance Mcp1 expression 
Atherosclerosis, T2DM and IR are characterized by chronic inflammation in different 
tissues.3-5, 19, 20 qPCR revealed increased expression of the proinflammatory cytokine 
Mcp1 in atherosclerotic plaque-rich aorta of apoE-/-Irs2+/- mice as well as in primary 
cultures of VSMCs and macrophages obtained from these animals vs. apoE-/- controls 
(Fig.5A). Given the results of our expression studies in aorta showing reduced mRNA 
level of Akt2, Hras 1 and Rras (Fig.4), we sought to assess whether defective signaling 
through AKT2 and/or ERK1/2 (a downstream effector of RAS signaling) might be linked to 
the increased Mcp1 expression associated with reduced expression of Irs2. Indeed, 
pharmacological inhibition of either AKT (inhibitor VIII) or ERK1/2 (U0126) increased 
Mcp1 mRNA expression in cultures of rat VSMCs (Fig.5B). Western blot analysis 
confirmed the inhibition of AKT and ERK, as indicated by reduced accumulation of 
phosphorylated (active) AKT1/2 and ERK1/2 (Fig.5B, pAKT1/2, pERK1/2) in treated 
VSMCs. Moreover, inhibitor VIII and U0126 markedly reduced, respectively, the 
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phosphorylation of p70S6K  (which is triggered upon AKT activation) and of serum-
inducible c-Fos upregulation (which depends on ERK1/2 activation) (Fig.5C), thus 
providing functional validation of the efficacy of these drugs in our experimental settings. 
 
 
Discussion 
Irs2-null mice develop T2DM- and MetS-like alterations (e.g. IR, hyperinsulinemia, 
glucose intolerance, hypertension, moderate hyperlipidemia).9-11 Recently, we and others 
reported that total ablation of Irs2 accelerates atherosclerosis in severely 
hypercholesterolemic apoE-/- mice.12, 13 Novel findings in the present study include: 1) the 
demonstration that increased risk of CVD in insulin-resistant versus insulin-sensitive MetS 
patients is associated with reduced expression of Irs2 in WMBCs, and that a moderate 
reduction in Irs2 expression is sufficient to accelerate atherosclerosis in severely 
hypercholesterolemic apoE-/-Irs2+/- mice, which display characteristics of MetS and IR; 2) 
the identification in aorta of changes in the expression of insulin-related genes potentially 
involved in augmented atherosclerosis in apoE-/-Irs2+/- mice, including the downregulation 
of Akt2 and Ras; and 3) the identification of defective IRS2/AKT and IRS2/RAS/ERK1/2 
signaling as mechanisms of upregulating the expression of proatherogenic MCP1.  
Reduced expression of Ins-r, Irs2 and Akt2 has been reported in pancreatic β-cells 
of T2DM/IR patients.16 However, our study is the first to analyze the expression of these 
signaling molecules in WMBCs from insulin-resistant and insulin-sensitive patients 
(Fig.1A). Notably, in accordance with the notion that AKT acts downstream of IRS2, we 
found a direct correlation between the level of Irs2 and Akt2 mRNA, both when 
considering all MetS patients (Fig.1B) and when analyzing separately insulin-sensitive 
and insulin-resistant subjects. We also found that levels of Irs2 and Akt2 mRNA were 
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inversely correlated with plasma insulin levels and the HOMA index only in insulin-
resistant patients (Fig.1C-F). Thus, hyperinsulinemia and IR in humans are associated 
with the downregulation of Irs2 and Akt2 in cell types which play major roles in the 
pathogenesis of T2DM and atherosclerosis. We also found similar level of Akt1 and Akt3 
in both groups of MetS patients and higher Irs1 expression in insulin-resistant subjects, 
perhaps as a compensatory mechanism, a possibility which deserves further 
investigation. Additional studies are also warranted to clarify the relative contribution of 
defined subpopulations of WMBCs in the establishment of the observed differences 
between insulin-sensitive and insulin-resistant MetS patients. 
We and others have previously reported that fat-fed apoE-/- mice with complete 
deficiency for IRS-2 exhibit features of MetS (severe dyslipidemia, hyperinsulinemia, 
glucose intolerance, IR) and accelerated atherosclerosis.12, 13 To address whether a 
moderate reduction in Irs2 expression (comparable to that which we observed in the 
WMBCs of insulin-resistant patients with MetS) might have pathological consequences in 
an animal model, we generated apoE-/-Irs2+/- mice which lack only one allele of Irs2. In 
response to high-fat feeding, these mice developed severe hypercholesterolemia (Total-
C>550 mg/dL), higher glucose intolerance and a trend towards hyperinsulinemia as 
compared to similarly hypercholesterolemic apoE-/- controls (Fig.2). This MetS-like 
phenotype of fat-fed apoE-/-Irs2+/- mice was associated with significantly enhanced aortic 
atherosclerosis, without changes in plaque composition (e.g., macrophage, VSMC and 
collagen content) (Fig.3, and Fig.I in www.ahajournals.org). Notably, none of the 
differences caused by partial Irs2 ablation were observed when mice were fed standard 
chow (Total-C<300 mg/dL), suggesting that reduced Irs2 expression can accelerate 
atherosclerosis only when combined with other features of MetS such as severe 
hypercholesterolemia. Interestingly, IR combined with severe hypercholesterolemia (>700 
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mg/dL) was also associated with severe atherosclerosis in fat-fed liver Ins-r-deficient 
mice.21 We also noted higher expression of the scavenger receptors SRA and CD36 and 
increased uptake of acLDL in apoE-/-Irs2+/- vs. apoE-/- macrophages (Fig.3C,D). Similar 
findings have been previously reported for Ins-r-deficient and ob/ob mouse 
macrophages.15, 22 Thus, increased macrophage uptake of modified LDLs through 
upregulation of SRA and CD36 appears to contribute to accelerated atherosclerosis in 
different MetS murine models. 
As fat-fed apoE-/-Irs2+/- mice seemed an appropriate model to investigate how 
impaired insulin-dependent signaling promotes atherosclerosis, we used aorta from these 
mice to investigate the consequences of reduced Irs2 on the expression of 84 genes 
implicated in insulin-signaling using a qPCR array (Table V, please see 
www.ahajournals.org). As expected, our gene profiling study confirmed a significant 
reduction in Irs2 mRNA in atheroma-rich aorta from fat-fed apoE-/-Irs2+/- vs. apoE-/- mice 
(Fig.4). The expression of Akt2 and Ras was also significantly diminished in aorta of fat-
fed apoE-/-Irs2+/- mice, indicating a correlation between a moderate reduction of Irs2 
expression and the downregulation of two major pathways which mediate insulin 
signaling. Remarkably, insulin-dependent IRS2/PI3K/AKT and IRS1/ERK1/2 signaling are 
impaired in macrophages from db/db and ob/ob diabetic mice,22, 23 and in human 
adipocytes from T2DM patients,24 respectively. It is also noteworthy that Akt2 ablation in 
the mouse causes major alterations in glucose homeostasis and insulin sensitivity, 
leading to IR and T2DM.25, 26 Therefore, our results extend these findings to the 
cardiovascular system by suggesting a mechanistic link between impaired AKT2- and 
RAS-dependent signaling in aortic tissue and accelerated atherosclerosis in fat-fed apoE-
/-Irs2+/- mice.  
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The proatherogenic role of MCP1 has been firmly established.27, 28 Thus, the 
upregulation of Mcp1 mRNA observed in aorta of fat-fed apoE-/-Irs2+/- mice (Fig.5A) may 
accelerate atherosclerosis in this model. Mcp1 expression was also higher in primary 
VSMCs and macrophages from apoE-/-Irs2+/- mice (Fig.5A). Moreover, this cytokine is 
upregulated in adipocytes exhibiting IR (IR-3T3-L1 and ob/ob adipocytes)29 and in 
platelets from diabetic patients.30 Our finding that pharmacological inhibition of AKT2 or 
ERK1/2 upregulates Mcp1 mRNA in rat VSMCs (Fig.5B) is consistent with the notion that 
accelerated atherosclerosis in MetS conditions is due, at least in part, to defective IRS2-
AKT2 and IRS2-RAS/ERK1/2 pathways and the resulting upregulation of Mcp1 in various 
cell types involved in atherothrombosis (e.g. VSMCs, macrophages, platelets, 
adipocytes). However, additional studies are needed to firmly establish causal 
relationships between human MetS states, Mcp1 upregulation, and dysfunctional IRS2-
AKT2- and IRS2-RAS/ERK1/2-dependent signaling. 
In summary, our studies demonstrate that WMBCs from MetS patients with IR 
display diminished expression of Irs2 and its downstream effector Akt2 compared to 
insulin-sensitive MetS patients, suggesting a mechanistic link between reduced IRS2 
expression and human metabolic diseases. Indeed, the moderate reduction of Irs2 
expression achieved in fat-fed apoE-/-Irs2+/- mice is sufficient to produce MetS-like 
symptoms and accelerate atherosclerosis. Our studies with aortic tissue, primary VSMCs 
and macrophages demonstrate that partial Irs2 inactivation impairs AKT2- and 
Ras/ERK1/2-dependent signaling, leading to augmented MCP1 expression and 
enhanced CD36 and SRA scavenger receptor expression and macrophage acLDL uptake 
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beyond hypercholesterolemia. These findings highlight defective IRS2-associated AKT2- 
and Ras/ERK1/2-dependent signaling as a potential mechanism underlying accelerated 
atherosclerosis in MetS/IR states.
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Figure Legends 
 
Fig.1. qPCR analysis in WMBCs from MetS patients. (A) Insulin-resistant compared to 
insulin-sensitive patients (=1). (B) Correlation between Irs2 and Akt2 mRNA for all MetS 
patients. (C-F) Regression analysis of Irs2 (C,D) and Akt2 (E,F) mRNA revealed 
significant associations with plasma insulin (C,E) and HOMA index (D,F) in insulin-
resistant patients. 
 
Fig.2. Metabolic characterization of mice. apoE-/- and apoE-/-Irs2+/- mice received either 
control (A,C,E) or atherogenic (B,D,F) diet. (A,B) Fasting plasma glucose and insulin. 
(C,D) Glucose tolerance test showing plasma glucose and insulin levels and the 
corresponding area under the curve (AUC). (E,F) Fasting plasma total cholesterol (Total-
C), HDL-C and TAG. 
 
Fig.3. Irs2 partial disruption increases atherosclerosis and macrophage acLDL 
uptake and scavenger receptor expression. (A) Atherosclerosis burden (Oil Red O-
stained aortic arch). (B) Neointimal content of Mac3-immunoreactive and SMα-actin-
immunoreactive cells and collagen (representative images from fat-fed apoE-/-Irs2+/-). 
(C,D) Macrophage AlexaFluor488-acLDL uptake and qPCR of CD36 and SRA (relative to 
apoE-/-). 
 
Fig.4. qPCR analysis of insulin-dependent genes in aortic arch of fat-fed mice (2 
months). The graph shows the mRNA levels of genes with p≤0.06 when comparing 
genotypes (Student’s t test; apoE-/-=1). A total of 84 genes were analyzed (please see 
Table V and Material and Methods in www.ahajournals.org). 
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Fig.5. Mcp1 upregulation by Irs2 partial inactivation and AKT2 or ERK1/2 
pharmacological inhibition. (A) qPCR in VSMCs, macrophages, and aorta from fat-fed 
mice (apoE-/-=1). (B) Rat VSMCs were subjected to qPCR (Left, untreated cells=1) and 
Western blot (Right, p-AKT1/2: phosphorylated AKT1/2; p-ERK1/2: phosphorylated 
ERK1/2). (C) Western blots in rat VSMCs.  
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Table 1: Demographic and clinical characteristics of MetS patients 
 
 Insulin-
sensitive 
Insulin-
resistant 
p value 
Gender (male/female) 22/3 26/4 0.797 
Age (years) 55±2 52±2 0.154 
BMI (kg/m2) 28.4±1.2 32.3±0.9 0.012 
Waist circumference (cm) 98±2 106±2 0.021 
SBP (mm Hg) 137±3 140±3 0.593 
DBP (mm Hg) 80±2 88±2 0.032 
Glucose (mmol/L) 101±2 106±3 0.152 
Insulin (pmol/L) 59.4±4.8 123.6±7.2 <0.001 
HOMA index 2.3±0.2 5.4±0.4 <0.001 
Total Cholesterol (mg/dL) 216±13 226±11 0.945 
LDL-cholesterol (mg/dL) 146±13 150±9 0.938 
HDL-cholesterol (mg/dL) 41±2 36±1 0.037 
Triglycerides (mg/dL) 153±16 154±12 0.983 
von Willebrand Factor (%) 115±13 116±7 0.924 
Fibrinogen (mg/dL) 287±12 288±13 0.984 
C-reactive protein (mg/dL) 0.31±0.04 0.27±0.03 0.339 
Oxidized LDL (U/L) 69±4 86±5 0.017 
MMP-9 (ng/mL) 9.9±1.2 14.0±1.4 0.038 
Obesity (%) 48 77 0.028 
Diabetes (%) 12 17 0.625 
Dyslipidemia (%) 84 97 0104 
Hypertension (%) 72 77 0.692 
Medication    
Antihypertensives (%) 40 47 0.713 
Statins (%) 8 7 1.000 
Oral hypoglycemics (%) 12 7 0.543 
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Supplementary Material 
 
Expanded figure legends 
 
Fig.1. mRNA levels of Irs2 and Akt2 in WMBCs are decreased in insulin-resistant 
MetS patients and inversely correlate with plasma insulin levels and HOMA index. 
(A) qPCR analysis of Irs1, Irs2, Akt1, Akt2 and Akt3 in WMBCs. Insulin-resistant 
patients are compared to insulin-sensitive patients (=1). Results were normalized by 
endogenous Gapdh expression, which was undistinguishable in both groups (p>0.05). 
(B) Correlation between Irs2 and Akt2 mRNA expression levels for all MetS patients. 
Regression analysis of Irs2 (C,D) and Akt2 (E,F) mRNA levels determined by qPCR 
revealed significant associations with plasma insulin levels (C,E) and HOMA index (D,F) 
in insulin-resistant MetS patients. 
 
Fig.2. Metabolic characterization of apoE-/-Irs2+/- and apoE-/- mice. Plasma glucose 
and insulin levels in mice fed control diet (A) or challenged with atherogenic diet for 3 
months (B) (apoE-/-Irs2+/-: n=10 and n=16, respectively; apoE-/-: n=13 and n=10, 
respectively) after overnight fasting. Glucose tolerance test in mice fed control diet (C) 
or atherogenic diet for 3 months (D), showing plasma glucose and insulin levels and the 
corresponding AUC (n=6). (E) Fasting plasma total cholesterol (Total-C), HDL 
cholesterol (HDL-C) and TAG of 10-month-old apoE-/-Irs2+/- (n=11) and apoE-/- (n=10) 
mice on control diet. (F) The same parameters were measured in mice before and after 
3 months of atherogenic diet (n=16 and n=18, respectively). 
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Fig.3. Partial disruption of Irs2 increased atherosclerosis and macrophage acLDL 
uptake and scavenger receptor expression. (A) Quantification of aortic arch 
atherosclerosis expressed as percentage of lesional area (stained by Oil Red O) for 
mice fed control diet for 10 months or atherogenic diet for 3 months. (B) Neointimal 
content (%) of Mac3-immunoreactive macrophages, SMα-actin-immunoreactive VSMCs 
and collagen in mice fed control diet for 10 months or atherogenic diet for 3 months. 
The photomicrograps show representative images (from fat-fed apoE-/-Irs2+/-mice). The 
discontinuous lines mark the approximate contour of the tunica media. (C) 
AlexaFluor488-acLDL uptake is increased in apoE-/-Irs2+/- macrophages. Results show 
the average of three independent experiments and are represented relative to apoE-/- 
(=1). (D) qPCR of CD36 and SRA in mouse macrophages (n=4).  
 
Fig.4. Aortic expression of genes related to insulin signaling. Gene profiling was 
performed in aortic arch tissue of apoE-/- and apoE-/-Irs2+/- mice fed atherogenic diet for 
2 months using a murine “Insulin signaling pathway qPCR Superarray” system, which 
allow the study of 84 genes related to insulin signaling (for details, see Table V and 
Expanded Material and Methods in Supplementary Material, www.ahajournals.org). 
mRNA levels in apoE-/-Irs2+/-mice are expressed relative to those in apoE-/- controls 
(=1). Asterisks indicate genes displaying statistically significant differences between 
genotypes. Three genes displayed borderline significance (p=0.06). 
 
Fig.5. Partial inactivation of Irs2 and pharmacological inhibition of AKT2 or 
ERK1/2 increases Mcp1 expression. (A) qPCR of Mcp1 in VSMCs (n= 3), 
macrophages (n= 3), and aortic tissue (n=5 pools of 2 vessels per genotype) obtained 
from fat-fed mice. Results were normalized with cyclophilin and were expressed relative 
to apoE-/- (=1). (B) Rat VSMCs were treated as indicated. Left: qPCR of Mcp1 (n=3). 
Results were normalized with Gapdh and expressed relative to untreated cells (=1, first 
bar). Right: Western blot analysis of the indicated proteins (p-AKT1/2: phosphorylated 
AKT1/2; p-ERK1/2: phosphorylated ERK1/2). *p<0.05; **p<0.03 vs. untreated cells. (C) 
Western blot analysis of downstream effectors of AKT (phospho-p70S6K) and ERK (c-
Fos) in rat VSMCs treated as indicated.  
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Expanded Materials and Methods 
 
Metabolic measurements in mice 
Circulating glucose and lipid levels in plasma of mice fasted overnight were measured 
using enzymatic procedures (WAKO, St. Louis, USA) and Glucometer Ascensia Elite 
(Bayer HealthCare). Insulin levels were determined by ELISA (Mercodia, Sweeden). 
HDL-cholesterol (HDL-C) was determined after precipitation of the apoB-containing 
lipoproteins with dextran-sulphate/MgCl2 (SIGMA, St. Louis, USA) as reported.1 For 
glucose tolerance test (GTT), mice were injected with glucose (intraperitoneally, 2g/Kg 
of body weight) and plasma and insulin glucose levels were analyzed at different time-
points. 
 
Quantification of atherosclerosis burden 
For mice fed standard chow or atherogenic diet for 3 months, the extent of 
atherosclerosis was determined by Oil Red O staining (80% methanol, 0.2% Oil Red O, 
SIGMA) of whole mounted aortic arch fixed with 4% paraformaldehyde/PBS as 
previously described.1 In mice fed atherogenic diet for 2 months, the aortic arch was 
snap-frozen for qPCR studies (see below) and lesion size was quantified as the intima-
to-media ratio in cross-sections of paraffin-embedded aortic root. A researcher blinded 
to genotype quantified the extent of atherosclerosis by computer-assisted morphometric 
analysis (SigmaScan, Pro5). 
 
Immunohistochemical analysis of atheromas 
Immunohistopathological examination of atheromas performed by a researcher blinded 
to genotype included the quantification of the content of macrophages, vascular smooth 
muscle cells (VSMCs), and collagen (Masson’s trichrome stain). VSMCs were identified 
with mouse anti-SMα-actin monoclonal alkaline phosphatase-conjugated antibody 
(clone 1A4, 1/20 dilution, a-5691, Sigma) and Fast Red substrate (Sigma). 
Macrophages were detected with a rat anti-Mac3 monoclonal antibody (clone M3/84, 
1/200 dilution, sc-19991, Santa Cruz Biotechnology), followed by biotin-conjugated goat 
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anti-rat secondary antibody (1/300, sc-2041, Santa Cruz Biotechnology), HRP-
Streptavidin (STAR5B, AbD SEROTEC) and DAB substrate (BUF021A, AbD 
SEROTEC). Slides were counterstained with hematoxylin. Images were captured with 
an Olympus CAMEDIA-C5060 wide zoom digital camera mounted on a 
stereomicroscope Axiolab, Zeiss).  
 
Primary cell culture 
Cultures were maintained at 37 °C in a humidified 5% CO2 atmosphere. Bone marrow-
derived macrophages were obtained from femoral bone marrow suspensions plated at 
3x106 cells/mL and differentiated for 7 days in the presence of DMEM/10%FBS/10% 
macrophage-colony stimulating factor2. Mouse and rat aortic VSMC cultures were 
obtained from thoracic aortas harvested from 3-5 month old animals after two digestions 
in HBSS/Fungizone medium as described elsewhere.2 Briefly, the first digestion 
consisted of type II collagenase (175U/mL, Worthington Biochemical Corp.) incubation 
to eliminate the adventitia. A second digestion with type II collagenase (175mg/mL) 
(Worthington) and type I Elastase (0.5mg/mL) (Sigma) gave rise to cell suspensions. 
VSMCs were cultured in 20% FBS/DMEM/Fungizone and used until passage 10. The 
purity of VSMCs was confirmed with anti-SMα-actin monoclonal alkaline phosphatase-
conjugated antibody (clone 1A4, 1/20 dilution, a-5691, Sigma) and Fast Red substrate 
(Sigma). 
 
Western blot analysis and pharmacological inhibition of kinases 
Protein extracts were obtained from VSMC cultures (typically 10 cm diameter plates) 
using ice-cold 50mM Tris-HCl buffer (pH 7.5) containing 1% Triton X-100, 150mM NaCl, 
1mM DTT and protease inhibitor Complete Mini cocktail (ROCHE, Mannheim, 
Germany). Polyacrilamide Gel Electrophoresis and Western blot analysis were done as 
reported 2 using the following primary antibodies: anti-ERK2 (1/500, sc-154), anti-
phospho-ERK1/2 (1/300, sc-7383), anti-c-Fos (1/300, sc-52), anti-Akt1/2 (1/1000, sc-
1619) from Santa Cruz Biotechnology, and anti-phospho-Akt1/2 (Ser473) (1/250, 9271) 
and anti-phosphop70S6K (Ser371) (1/1000, 9208) from Cell Signaling Technology. HRP 
conjugated secondary antibodies (1/300, Santa Cruz Biotechnology) used were: goat 
anti-mouse IgG-HRP (sc-2005), goat anti-rabbit IgG-HRP (sc-2004) and donkey anti-
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goat IgG-HRP (sc-2056). Immunocomplexes were detected with ECL detection kit 
(Amersham Biosciences, Piscataway, USA). 
For inhibition studies, rat aortic VSMCs were incubated overnight with the MEK 
inhibitor U0126 (10 μM, Promega) or the AKT Inhibitor VIII (1 μM, Calbiochem). 
Effective inhibition was first confirmed by Western blot analysis of the phosphorylated 
(active) forms of AKT (p-AKT) and ERK1/2 (p-ERK1/2). Inhibition was also validated by 
Western blot of c-Fos and phosphorylated p70S6K (p-p70S6K) as downstream targets of 
ERK1/2 and AKT, respectively. For c-Fos expression, cells were starved for 48h, pre-
incubated 1h with or without the MEK inhibitor U0126 and then serum-stimulated for 2h. 
 
Uptake of acetyladed-low-density lipoproteins (Ac-LDL) 
Bone marrow-macrophages from apoE-/- (n=3) and apoE-/-Irs2+/- (n=3) mice were 
incubated for 4 hours with AlexaFluor488-acLDL (1 μg/mL, Invitrogen) in Serum-Free 
media. After incubation, cells were recovered in complete medium and AlexaFluor488-
acLDL uptake was quantified as the median fluorescence intensity (arbitrary units) using 
a FACsCanto cytometer (BD Bioscience).  
 
Gene expression analysis by quantitative real-time PCR (qPCR) 
The TRIzol Reagent (Invitrogen) was used for extracting RNA from aortic tissue of mice 
fed atherogenic diet for 2 months, from mouse cells and from human white mononuclear 
blood cells (WMBCs) isolated from peripheral blood samples with Lymphoprep as 
previously described.3 RNA purity and concentration was determined by the A260/280 
ratio.  
The studies of Fig.3D and 5A were carried out with RNA (0.5-1μg) retro-
transcribed with Superscript III First Strand Synthesis Supermix and Platinum 
Quantitative PCR Supermix-UDG with Rox dye (both from Invitrogen). Reactions were 
run on a thermal Cycler 7500 Fast System and results were analyzed with the software 
provided by the manufacturer (Applied Biosystems). The following primers (Forward: 
Fw; Reverse: Rv) were designed using the Primer Express programme (Applied 
Biosystems):  
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Mouse Cd36:  
Fw 5’-TCGGAACTGTGGGCTCATTG-3’ 
Rv 5’-CCTCGGGGTCCTGAGTTATATTTTC-3’ 
Mouse Sra:  
Fw 5’-CATGAACGAGAGGATGCTGACT-3 
Rv 5’-GGAAGGGATGCTGTCATTGAA-3’ 
Mouse Mcp1:  
Fw 5’-GCCCAGCACCAGCACCAG-3’ 
Rv 5’-GGCATCACAGTCCGAGTC-3’  
Mouse cyclophilin:  
Fw 5’-TGGAGAGCACCAAGACAGACA-3’ 
Rv 5’-TGCCGGAGTCGACAATGAT-3’ 
Rat Mcp1:  
Fw 5’-GCTGCTACTCATTCACTGGCAA-3’ 
Rv 5’-TGCTGCTGGTGATTCTCTTGTA-3’ 
Rat Gapdh:  
Fw 5’-TGCACCACCAACTGCTTA-3’ 
Rv 5’-GGATGCAGGGATGATGTTC-3’ 
Human Irs1:  
Fw-5’-CGGAGAGCGATGGCTTCTC-3’  
Rv 5’-GTTTGTGCATGCTCTTGGGTTT-3’  
Human Irs2:  
Fw-5’-CCGACGCCAAGCACAAGTA-3’  
Rv 5’-CGGCCACGGCGAAGTA-3’  
Human Akt1:  
Fw 5’-CCGACGCCAAGCACAAGTA-3’  
Rv 5’-CGGCCACGGCGAAGTA-3’ 
Human Akt2:  
Fw 5’-CAAGGATGAAGTCGCTCACACA-3’  
Rv 5’-GAACGGGTGCCTGGTGTTC-3’ 
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Human Akt3:  
Fw 5’-CCTTGAAATATTCCTTCCAGACAAA-3’  
Rv 5’-ACAGCTCGCCCCCATTAAC-3’ 
Human Gapdh:  
Fw 5’-ACCACAGTCCATGCCATCAC-3’  
Rv 5’-TCCACCACCCTGTTGCTGTA-3’ 
 
The studies of Fig. 4 were done using the Mouse Insulin Signaling Pathway RT2 
Profiler PCR Array System, which allows the analysis of 84 genes related to the insulin-
signaling pathway and housekeeping genes for normalization (Superarray Bioscience 
Cat. # PAMM-030, see Table V and 
http://www.superarray.com/rt_pcr_product/HTML/PAMM-030A.html). For each array, 
RNA was extracted with TRIzol Reagent from a pool of 2 aortic archs and cDNA was 
synthesized using the Reaction-Ready First Strand cDNA synthesis kit (SuperArray 
Bioscience). For each genotype, 5 independent qPCR arrays were run using the 7500 
Fast System Light Cycler and analysis was performed according to the manufacturer’s 
recommendations (Applied Biosystems). Expression in apoE-/-Irs2+/- mice was 
expressed relative to that in apoE-/- mice (=1). 
 
Statistical analysis 
Data are presented as mean±SEM. Differences among mouse groups were evaluated 
by one-way ANOVA with Fisher’s post-hoc test (Statview, SAS institute, Cary, USA). 
Differences in the demographic and clinical characteristics between insulin-resistant and 
insulin-sensitive patients were assessed by Student’s t or Mann-Whitney´s U test. The 
χ2 analysis was used to analyze differences among qualitative variables. The Pearson 
test was used to assess associations between continuous variables in human studies. 
Multivariate linear regression analysis was performed to evaluate factors related to Irs2 
and Akt2 human expression. The area under the curve (AUC) was calculated with the 
R-Project programme. Statistical significance was taken at p≤0.05. 
 
 8
Results 
 
Analysis of all MetS patients (insulin-sensitive + insulin-resistant) revealed a significant 
and inverse correlations of WMBC Irs2 mRNA levels with plasma insulin levels 
(r2=0.087, p=0.031) and HOMA index (r2=0.074, p=0.050). These associations 
remained statistically significant in a multivariate analysis after adjusting for age, 
diastolic blood pressure (DBP), body mass index (BMI), and HDL-cholesterol (Tables I 
and II). Similarly, Akt2 mRNA levels in WMBC were negatively associated with plasma 
insulin levels (r2=0.110, p=0.016) and HOMA index (r2=0.113, p=0.050) when analyzing 
all MetS patients, and these associations remained statistically significant in a 
multivariate analysis after adjusting for age, DBP, BMI, and HDL-cholesterol (Tables III 
and IV).  
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Table I: Association WMBC Irs2 expression/plasma insulin in multiple linear regression analysis 
 β p * Partial r2 (%) 
Plasma insulin levels (pmol/L)  -0.25 0.041 8.7 
BMI (kg/m2) 0.004 0.861 0.1 
HDL-cholesterol (mg/dL) -0.11 0.165 2.6 
DBP (mm Hg) -0.003 0.749 0.2 
Age (years) 0.13 0.144 3.9 
r2 for the total population was 15.5% 
 
 
Table II: Association WMBC Irs2 expression/HOMA index in multiple linear regression analysis 
 β p * Partial r2 (%) 
HOMA index  -0.084 0.045 7.4 
BMI (kg/m2) 0.003 0.872 0.2 
HDL-cholesterol (mg/dL) -0.11 0.189 1.8 
DBP (mm Hg) -0.002 0.813 0.1 
Age (years) 0.16 0.079 5.9 
r2 for the total population was 15.4% 
 
 
Table III: Association WMBC Akt2 expression/plasma insulin in multiple linear regression analysis 
 β p * Partial r2 (%) 
Plasma insulin levels, pmol/L  -0.023 0.018 11.0 
BMI (kg/m2) 0.022 0.180 2.0 
HDL-cholesterol (mg/dL) -0.0011 0.825 0.1 
DBP (mm Hg) -0.006 0.410 1.1 
Age (years) 0.013 0.078 5.7 
r2 for the total population was 19.9% 
 
Table IV: Association WMBC Akt2 expression/HOMA index in multiple linear regression analysis 
 β p * Partial r2 (%) 
HOMA index  -0.090 0.006 11.3 
BMI (kg/m2) 0.024 0.151 2.2 
HDL-cholesterol (mg/dL) -0.002 0.805 0.1 
DBP (mm Hg) -0.005 0.526 0.6 
Age (years) 0.016 0.028 8.8 
r2 for the total population was 23% 
p values in all tables are adjusted for BMI, DBP, HDL-cholesterol and age. 
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Table V: List of the 84 genes analyzed in the Insulin Signaling Pathway RT2 Profiler PCR Array System 
Insulin Receptor-associated 
Proteins: 
Ins1, Insl3, Irs1, Irs2, Sorbs1, Igf1r, Igfbp1, Cbl, Grb10, Grb2, Dok1, Dok2, Dok3, Eif4ebp1, Frs2, Frs3, 
Gab1, Nck1, Ppp1ca, Ptpn1, Ptprf, Shc1 
PI-3 Kinase Pathway: 
 
Akt1, Akt2, Akt3, Eif2b1, Frap1, Pdpk1, Pik3ca, Pik3cb, Pik3r1, Pik3r2, Prkcc, Prkci, Prkcz, Adra1d, 
Bcl2l1, Dusp14, G6pc, G6pc2, Hk2, Igfbp1, Pck2, Serpine1, Srebf1, Ucp1, Vegfa 
MAPK Pathway: 
 
Araf, Braf, Dok2, Dok3, Gab1, Grb2, Hras1, Kras, Map2k1, Mapk1, Raf1, Rps6ka1, Rras, Rras2, Shc1, 
Sos1, Bcl2l1, Ercc1, Fos, Nos2, Klf10 (Tieg1), Ucp1 
Primary Target Genes for Insulin: Cebpb, Fos, Jun, Lep, Prl 
Secondary Effector Target Genes 
for Insulin Signaling: 
Npy, Pck2, Tg 
Target genes for PPARγ: Acox1, Cfd (Adn), Cap1, Cebpb, Gpd1, Pck2, Pparg, Retn, Slc27a4 
Target genes for SREBP1: Acaca, Fbp1, G6pc, Gck, Pck2, Pklr 
Carbohydrate Metabolism: Fbp1, G6pc, Gck, Gpd1, Hk2, Ins1, Lep, Pck2, Pklr, Ppp1ca, Slc2a1, Sorbs1. 
Lipid Metabolism: Ldlr, Lep, Srebf1, Acox1, Slc27a4, Sorbs1, Araf, Prkcc, Prkci, Prkcz, Raf1, Shc1 
Protein Metabolism: 
 
Dusp14, Ppp1ca, Ptpn1, Ptprf, Akt1, Akt2, Akt3, Araf, Gsk3b, Igf1r, Map2k1, Mapk1, Pdpk1, Pik3ca, 
Pik3r1, Prkcc, Prkci, Prkcz, Raf1, Rps6ka1, Eif2b1, Eif4ebp1, Ppp1ca, Hras1, Prkci, Rras2, Bcl2l1, 
Cebpa, Cebpb, Dok3, Frs2, Gab1, Gck, Grb10, Grb2, Jun, Ldlr, Lep, Nck1, Nos2, Pik3r2, Serpine1, Shc1, 
Sorbs1, Sos1, Ucp1 
Transcription Factors and 
Regulators: 
Aebp1, Cebpa, Cebpb, Fos, Jun, Pparg, Srebf1, Klf10 (Tieg1) 
Cell Growth and Differentiation: 
 
Gsk3b, Hras1, Igf2, Jun, Kras, Mapk1, Irs2, Lep, Nos2, Frs2, Igf1r, Igf2, Igfbp1, Lep, Shc1, Vegfa, Cebpa, 
Cebpb, Map2k1, Pik3r1, Pparg. 
Classification in different categories as indicated by the manufacturer (SuperArray Bioscience; 
http://www.superarray.com/rt_pcr_product/HTML/PAMM-030A.html). Note that some genes are included in more than one category. 
Shown in colour are the 14 genes included in Figure 4 which exhibited downregulation (in red) or upregulation (in green) in the aortic 
arch of fat-fed apoE-/-Irs2+/- versus apoE-/- mice. Genes shown in black did not display statistically significant differences. 
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Figure I: Partial disruption of Irs2 increases atherosclerosis burden but does not affect plaque composition. Aortic root cross-
sections were obtained from mice fed the atherogenic diet for two months. (A) Atherosclerosis burden determined as the intima-to-media 
ratio. Results are expressed relative to apoE-/- mice (=1). (B) Neointimal content of macrophages, VSMCs and collagen was quantified 
using anti-Mac-3, anti-SM α–actin and Masson’s Trichrome staining, respectively. Results represent the percentage of area occupied by 
macrophages, VSMCs and collagen versus total area of atheroma. The photomicrograps show representative images of the stainings 
(from apoE-/-Irs2+/-mice). The discontinuous lines mark the approximate contour of the tunica media. Statistically significant differences 
between genotypes were only observed for the intima-to-media-ratio (p=0.02), as assessed by Student’s t-test. 
